Solitary fi brous tumor of the pleura (SFTP) is uncommon and has uncertain and unpredictable prognosis. Rarely attempted, the standardization of prognostic criteria has, so far, failed. 1 , 2 Th e eff ort from Tapias et al 3 recently reported in CHEST (January 2015) is, therefore, very welcome. By fi rst proposing 4 and subsequently validating 3 a scoring system able to predict the recurrence aft er (radical) surgical resection for SFTP, they have provided a benchmark for discussion on the issue. Inspired by this, we have analyzed data from our multicentric malig nant SFTP database, 5 testing the accuracy of the "Tapias score. "
Among 50 male patients with SFTP, 43 were eligible. 3 Th e Tapias score (0-6) was as follows: n 5 3, 2 points; n 5 7, 3 points; n 5 13, 4 points; n 5 18, 5 points; and n 5 2, 6 points . Tapias score 5 0 was not recorded. With a cutoff Ն 3, 3 , 4 40 patients (93%) were labeled as high risk for recurrence, and three (7%) were labeled as low risk. Th e Cox regression analysis was reanalyzed, exploring the value of Tapias score in predicting recurrence or death ( Table 1 ) . 
We registered at follow-up 12 recurrences (30%) in the high-risk group vs none in the low-risk group ( P 5 .06), confi rming the usefulness of the Tapias score as a predictor of recurrence. In addition, malignant pleural eff usion and chest wall invasion signifi cantly increased the risk of recurrence ( P 5 .03 and .007, respectively). Th e completeness of resection was the only independent factor infl uencing the prognosis on multivariate analysis ( P 5 .01).
What clearly emerges from this comparison is that the number of recurrences observed in the two clinical series (nine cases in the Tapias et al 3 study and 12 in our series) is too low to represent a robust basis for a score system analysis as suggested by the wide ranges in CIs in both analyses. Moreover, the population investigated in Tapias et al 3 was not completely representative of the biologic spectrum of such neoplasms, whereas 70% of all patients were low-risk subjects (relapse, 8%). More aggressive cases of SFTP were present in our study, with a higher percentage of recurrences (12 cases, 27.9%).
Consequently, we strongly believe that the Tapias score represents a remarkable step toward a better comprehension of such rare neoplasms and an excellent basis to further generate a more accurate score system analysis on larger and more homogeneous datasets of patients, with the number of recurrences as the principal determinant of the sample size. As well, we believe that other clinical features (eg, chest wall invasion, malignant pleural eff usion) probably deserve more attention in prognostic stratifi cation aft er radical surgery. We sincerely thank Dr Lococo and colleagues for their comments on our recent article in CHEST 1 validating a scoring system to predict recurrence aft er complete resection of solitary fi brous tumors of the pleura (SFTPs). We commend the expeditious eff ort of applying the score to a multiinstitutional population of patients with resected "malignant" SFTPs. 2 Th e results appear to further support the scoring system as a useful clinical tool that outperformed historical criteria (ie, England's criteria), even when applied to a higher risk population harboring a malignant phenotype of SFTPs.
We agree with the authors' comment that the number of events in our study (ie, SFTP recurrences) is too low to represent a robust basis for a score-system analysis. However, the low incidence of this neoplasm 3 precludes the accumulation of large patient samples hampering prospective studies. Published literature consists mostly of single-institution retrospective case series, with no standardization of prognostic criteria. In spite of these limitations, it is our intention to provide a basis to organize the evaluation of oncologic outcomes of patients undergoing surgical treatment of SFTP. Including the population of Lococo et al, 2 the proposed scoring system has now been applied to three independent cohorts of patients accounting for a total of 215 subjects with SFTPs. 1 , 2 , 4 In all cases, it has performed well in terms of its capacity to classify patients according to their risk of SFTP recurrence aft er complete surgical resection.
We respectfully disagree with the statement that the population studied in the external validation cohort 1 does not represent all of the biologic spectrum of SFTP.
While it is true that we excluded patients with multifocal and metastatic disease, incompletely resected SFTPs, and those medically unfi t to undergo surgery, we included all patients treated at a reference surgical center. One would expect that this would capture most cases as they spontaneously occur in the hospital's area of infl uence.
Finally, we agree with the comment that other variables deserve more attention in the prognostic stratification of patients with SFTP. In concordance with their observation, in our score development cohort 4 we found that the presence of a pleural eff usion, as well as a symptomatic presentation, and a Ki67 proliferation index . 10% were associated with SFTP recurrence on univariate analysis. Unfortunately, these variables could not be included in our regression models given the paucity of events and our small sample size. We believe that the predictive ability of the present score can be improved by incorporating additional clinical variables, but especially, molecular parameters, while analyzing larger multiinstitutional populations. 
